Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension

• Үндсэн зохиолчид: Wenxing Dong (Зохиогч), Zhe Zhang (Зохиогч), Mingming Chu (Зохиогч), Peng Gu (Зохиогч), Min Hu (Зохиогч), Lulu Liu (Зохиогч), Jingbin Huang (Зохиогч), Rong Zhang (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Frontiers Media S.A., 2023-08-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Objective: Adding selexipag to the combined treatment of endothelin receptor antagonists (ERA) and phosphodiesterase 5 inhibitor (PDE5i) reduces the risk of clinical worsening events in patients with pulmonary arterial hypertension (PAH) but at a considerably higher cost. This study evaluated the co...